TIE2 links MEKK3-KLF2/4 and PI3K signaling in cerebral cavernous malformation.

Summary

Using human specimens, two mouse CCM models, and primary endothelial cells, the authors show that TIE2—not VEGFR2—links MEKK3–KLF2/4 activation to PI3K signaling in CCM. Genetic or pharmacologic TIE2 inhibition nearly abolished lesion formation, establishing TIE2 as a causal node and therapeutic target.

Key Findings

• CCM lesions in humans and mice exhibit markedly increased phospho-TIE2 and TIE2 expression driven by MEKK3–KLF2/4.
• Genetic or pharmacologic inhibition of TIE2 nearly completely rescues CCM formation in mouse models.
• No evidence supports augmented VEGFR2 signaling in CCM; VEGFR2 blockade did not reduce CCM lesions.

Clinical Implications

TIE2 inhibitors or ligand-modulating strategies could be developed for CCM, and selection biomarkers (elevated phospho-TIE2) may guide patient stratification. The study also deprioritizes VEGFR2 as a target in CCM.

Limitations

• Preclinical study; no human interventional data yet
• Long-term safety and efficacy of TIE2 blockade remain to be established

Future Directions

Develop selective TIE2 inhibitors or ligand-directed approaches, validate phospho-TIE2 as a biomarker, and design early-phase trials in genetically defined CCM populations.